Professional
Added to YB: 2024-12-16
Pitch date: 2024-12-10
NVO [bullish]
Novo Nordisk A/S
-53.48%
current return
Author Info
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 108.29
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
growth
Pine Stone Asset Management Portfolio Holding: Novo Nordisk A/S
NVO: Insulin leader since 2009, disrupted industry with GLP-1 drugs (Ozempic/Wegovy) for diabetes & weight loss. Huge market, sticky customers. Strong organic growth, R&D focus. Eli Lilly main competitor. Trimmed position due to recent excitement, but still bullish on long-term prospects. Oral drug in development.
Read full article (5 min)